Palisade Bio (PALI) Total Debt (2013 - 2025)

Palisade Bio (PALI) posted quarterly Total Debt of $235000.0 for Q3 2025, up 256.06% quarter-over-quarter from $66000.0 in Q2 2025.

Palisade Bio (PALI) Total Debt (2013 - 2025) Analysis & Trends

Palisade Bio (PALI) has reported Total Debt for 10 consecutive years, with $235000.0 the latest figure, recorded in Q3 2025.

In Q3 2025, Total Debt changed N/A year-over-year to $235000.0; the TTM figure through Sep 2025 stood at $235000.0 (changed N/A YoY), while the FY2023 annual figure was $143000.0, changed N/A from the prior year.
Total Debt improved to $235000.0 in Q3 2025 per PALI's latest filing, from $66000.0 in the prior quarter.
Across five years, Total Debt topped out at $1.1 million in Q2 2021 and bottomed at $66000.0 in Q2 2025.
Historically, Total Debt has averaged $254125.0 across 4 years, with a median of $143000.0 in 2023.
Annual changes were most pronounced in 2021 — Total Debt plunged 92.38% — and 2025, when it tumbled 51.75%.
Palisade Bio's Total Debt stood at $87000.0 in 2021, then jumped by 64.37% to $143000.0 in 2023, then gained by 4.2% to $149000.0 in 2024, then surged by 57.72% to $235000.0 in 2025.
Business Quant data shows PALI's Total Debt at $235000.0 in Q3 2025, $66000.0 in Q2 2025, and $69000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.07 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	9.34 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Palisade Bio	372.94 Mn	247.74 Mn	-	-

Download Data